1.065USD+0.47%Mkt Cap: 69.93M USDP/E: —Last update: 2026-05-26
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap69.93M USD
Enterprise Value31.14M USD
Revenue (TTM)9.14M USD
Gross Profit-95.53M USD
Net Income (TTM)-129.77M USD
Revenue/Share0.1520 USD
Last Price1.065 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees142
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.15
PEG—
EV/EBITDA-0.25
EV/Revenue3.41
P/S7.30
P/B0.47
EPS (TTM)-0.96
EPS (Forward)-0.89
52W Range
0.882011% of range2.570
52W High2.570 USD
52W Low0.8820 USD
Profitability
Gross Margin0.00%
Oper. Margin-2967.31%
EBITDA Margin0.00%
Profit Margin-1256.81%
ROE-105.40%
ROA-56.72%
Growth
Revenue Growth-54.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-135.32M USD
CapEx (TTM)4.41M USD
FCF Margin-920.62%
FCF Yield-120.28%
Net Debt-35.52M USD
Net Debt/EBITDA0.29
Balance Sheet
Debt/Equity0.76
Current Ratio6.65
Quick Ratio6.41
Book Value/Sh2.164 USD
Cash/Share1.960 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)6.000 USD
Target Range5.000 USD – 7.000 USD
# Analysts4
Ownership
Shares Out.61.07M
Float54.51M
Insiders0.20%
Institutions59.39%
Short Interest
Short Ratio0.7d
Short % Float2.20%
Short % Out.1.45%
Shares Short870.16K
Short (prev mo.)1.89M
Technical
SMA 501.111 (-4.1%)
SMA 2001.341 (-20.6%)
Beta1.06
S&P 52W Chg28.31%
Avg Vol (30d)890.92K
Avg Vol (10d)726.77K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—